Abstract

Biallelic mutations of the gene encoding the transcription factor NEUROG3 are associated with a rare disorder that presents in neonates as generalized malabsorption - due to a complete absence of enteroendocrine cells - followed, in early childhood or beyond, by insulin-dependent diabetes mellitus (IDDM). The commonly delayed onset of IDDM suggests a differential requirement for NEUROG3 in endocrine cell generation in the human pancreas versus the intestine. However, previously identified human mutations were hypomorphic and, hence, may have had residual function in pancreas. We report 2 patients with biallelic functionally null variants of the NEUROG3 gene who nonetheless did not present with IDDM during infancy but instead developed permanent IDDM during middle childhood ages. The variants showed no evidence of function in traditional promoter-based assays of NEUROG3 function and also failed to exhibit function in a variety of potentially novel in vitro and in vivo molecular assays designed to discern residual NEUROG3 function. These findings imply that, unlike in mice, pancreatic endocrine cell generation in humans is not entirely dependent on NEUROG3 expression and, hence, suggest the presence of unidentified redundant in vivo pathways in human pancreas capable of yielding β cell mass sufficient to maintain euglycemia until early childhood.

Highlights

  • NEUROG3 is a basic helix-loop-helix transcription factor that drives endocrine lineage generation in the gut, pancreas, and hypothalamus [1,2,3]

  • An in vitro directed–differentiation protocol fails to generate any significant number of pancreatic endocrine cells from human pluripotent stem cells if NEUROG3 function is disabled by gene editing [10, 11]

  • It has been concluded that the NEUROG3 mutations affecting patients exhibiting delayed-onset insulin-dependent diabetes mellitus (IDDM) (e.g., p.R107S) must be hypomorphic, displaying insufficient transactivating activity to enable generation of enteroendocrine cells (EECs) in the gut, but retain sufficient activity to initiate some minimal level of pancreatic endocrine differentiation during development [8, 11]

Read more

Summary

Introduction

NEUROG3 is a basic helix-loop-helix (bHLH) transcription factor that drives endocrine lineage generation in the gut, pancreas, and hypothalamus [1,2,3]. Human neonates with biallelic dysfunctional NEUROG3 present clinically with enteric anendocrinosis (MIM:#610370), characterized by generalized malabsorption and an absence of enteroendocrine cells (EECs) [4,5,6] As these children age, hypogonadotropic hypogonadism and short stature become evident [7], and at a variable age (from 20 days to more than 23 years of age), they develop insulin-dependent diabetes mellitus (IDDM) [8, 9]. NEUROG3 deletion experiments in pigs [3, 12] and mice [3] have demonstrated failure of endocrine cell generation in the developing pancreas, resulting in a permanent neonatal diabetes mellitus (PNDM) phenotype. It has been concluded that the NEUROG3 mutations affecting patients exhibiting delayed-onset IDDM (e.g., p.R107S) must be hypomorphic, displaying insufficient transactivating activity to enable generation of EECs in the gut, but retain sufficient activity to initiate some minimal level of pancreatic endocrine differentiation during development [8, 11]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call